Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront

The candidate has shown potential in treating B-cell mediated autoimmune diseases

- PMLiVE

AstraZeneca’s Imfinzi granted EC approval for limited-stage small cell lung cancer

The drug is already approved in the EU to treat extensive stages of the disease

- PMLiVE

Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy

The company said it is planning to file regulatory applications for OAV101 IT this year

- PMLiVE

Harnessing AI and big data in clinical research

By Sheila Kelly

- PMLiVE

Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study

It is estimated that nearly 320,000 people will be diagnosed with the disease in the US this year

- PMLiVE

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

Approximately 20,000 cases of the disease are diagnosed in the US every year

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

Breaking down the barriers

Liberating omnichannel’s full potential

- PMLiVE

AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition

The biotech’s ENaBL platform enables cell therapies to be administered through an IV injection

- PMLiVE

NICE recommends Pharming’s Joenja as first treatment for ultra-rare immune disease APDS

Approximately 40 to 50 people in the UK are known to be living with the inherited disorder

- PMLiVE

Boehringer Ingelheim and Salipro Biotech enter drug development partnership

The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

- PMLiVE

Communicating value to US Payers: Insights for Pharma and Medtech

What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging...

Petauri Evidence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links